$CMPS
Compass Pathways PLC Stock $cmps

$cmps Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000162828022003651 Filed on February 24, 2022

Income Statement

Concept	2021	2020 Q4	2020
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$30.54M	$4.840M	$21.20M
YoY Change	44.06%	-43.83%	145.94%
% of Gross Profit
Research & Development	$44.03M	$4.540M	$23.37M
YoY Change	88.42%	-63.86%	85.99%
% of Gross Profit
Depreciation & Amortization	$200.0K	$30.00K	$100.0K
YoY Change	100.0%	-25.0%	0.0%
% of Gross Profit
Operating Expenses	$83.22M	$9.380M	$51.39M
YoY Change	61.93%	-55.71%	142.66%
Operating Profit	-$83.22M		-$51.39M
YoY Change	61.93%		142.66%
Interest Expense	$1.990M	-$8.450M	-$11.70M
YoY Change	-117.01%
% of Operating Profit
Other Income/Expense, Net	$11.68M	$1.070M	-$8.909M
YoY Change	-231.08%	-32.36%	-663.15%
Pretax Income	-$71.54M	-$18.90M	-$60.30M
YoY Change	18.64%	-3.56%	207.71%
Income Tax	$199.0K	-$90.00K	$32.00K
% Of Pretax Income
Net Earnings	-$71.74M	-$18.81M	-$60.33M
YoY Change	18.91%	-4.09%	207.64%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.79		-$3.55
Diluted Earnings Per Share	-$1.79	-$523.5K	-$3.55
COMMON SHARES
Basic Shares Outstanding	40.00M shares		16.99M shares
Diluted Shares Outstanding	40.00M shares		16.99M shares

Balance Sheet

Concept	2021	2020 Q4	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$273.2M	$190.3M	$190.3M
YoY Change	43.59%		661.2%
Cash & Equivalents		$190.3M
Short-Term Investments
Other Short-Term Assets	$10.84M	$509.0K	$6.300M
YoY Change	72.08%		215.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$295.3M	$202.4M	$202.4M
YoY Change	45.9%		528.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.094M	$245.0K	$200.0K
YoY Change	1947.0%		0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$525.0K	$500.0K	$500.0K
YoY Change	5.0%
Other Assets	$979.0K	$57.00K	$300.0K
YoY Change	226.33%
Total Long-Term Assets	$5.598M	$1.052M	$1.100M
YoY Change	408.91%		450.0%
TOTAL ASSETS
Total Short-Term Assets	$295.3M	$202.4M	$202.4M
Total Long-Term Assets	$5.598M	$1.052M	$1.100M
Total Assets	$300.9M	$203.5M	$203.5M
YoY Change	47.86%		528.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.564M	$2.747M	$2.700M
YoY Change	-5.04%		107.69%
Accrued Expenses	$12.28M	$3.500M	$3.500M
YoY Change	250.71%		150.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.11M	$6.895M	$6.900M
YoY Change	118.94%		-71.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.379M
YoY Change
Total Long-Term Liabilities	$1.379M	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.11M	$6.895M	$6.900M
Total Long-Term Liabilities	$1.379M	$0.00	$0.00
Total Liabilities	$16.49M	$6.895M	$6.900M
YoY Change	138.93%		-71.13%
SHAREHOLDERS EQUITY
Retained Earnings		-$97.90M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$284.4M	$196.6M	$196.6M
YoY Change
Total Liabilities & Shareholders Equity	$300.9M	$203.5M	$203.5M
YoY Change	47.86%		528.09%

Cashflow Statement

Concept	2021	2020 Q4	2020
OPERATING ACTIVITIES
Net Income	-$71.74M	-$18.81M	-$60.33M
YoY Change	18.91%	-4.09%	207.64%
Depreciation, Depletion And Amortization	$200.0K	$30.00K	$100.0K
YoY Change	100.0%	-25.0%	0.0%
Cash From Operating Activities	-$67.75M	-$16.75M	-$41.38M
YoY Change	63.71%	46.16%	132.3%
INVESTING ACTIVITIES
Capital Expenditures	$334.0K	-$30.00K	$131.0K
YoY Change	154.96%	-72.73%	-20.61%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$10.00K	-$500.0K
YoY Change	-100.0%
Cash From Investing Activities	-$334.0K	-$30.00K	-$628.0K
YoY Change	-46.82%	-72.73%	280.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$154.8M		$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$156.6M	20.00K	$194.2M
YoY Change	-19.32%	-99.89%	956.4%
NET CHANGE
Cash From Operating Activities	-$67.75M	-16.75M	-$41.38M
Cash From Investing Activities	-$334.0K	-30.00K	-$628.0K
Cash From Financing Activities	$156.6M	20.00K	$194.2M
Net Change In Cash	$82.99M	-16.76M	$165.4M
YoY Change	-49.82%	-346.11%	7862.06%
FREE CASH FLOW
Cash From Operating Activities	-$67.75M	-$16.75M	-$41.38M
Capital Expenditures	$334.0K	-$30.00K	$131.0K
Free Cash Flow	-$68.08M	-$16.72M	-$41.51M
YoY Change	64.0%	47.31%	130.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001816590
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.00086133
CY2020Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	8.8028
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Security12b Title Security12bTitle	American Depositary Shares, each representing one ordinary share, par value of £0.008 per share
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-39522
CY2021	dei	Entity Registrant Name EntityRegistrantName	COMPASS Pathways plc
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	33 Broadwick Street
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	London
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	W1F 0DQ
CY2021	dei	Entity Address Country EntityAddressCountry	GB
CY2021	dei	City Area Code CityAreaCode	646
CY2021	dei	Local Phone Number LocalPhoneNumber	905-3974
CY2021	dei	Trading Symbol TradingSymbol	CMPS
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	332000	USD
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	825000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42019874	shares
CY2021	dei	Auditor Firm AuditorFirmId	876
CY2021	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2021	dei	Auditor Location AuditorLocation	Reading, United Kingdom
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	273243000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190327000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	104000	USD
CY2020Q4	us-gaap	Prepaid Taxes PrepaidTaxes	0	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	29000	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	21621000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	12048000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	295300000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	202404000	USD
CY2021Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	525000	USD
CY2020Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	529000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	398000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	245000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3696000	USD
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	766000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	221000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	213000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	57000	USD
CY2021Q4	us-gaap	Assets Assets	300898000	USD
CY2020Q4	us-gaap	Assets Assets	203456000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2564000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2747000	USD
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	10308000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	444750000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4148000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	279480000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	196561000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8840000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2235000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15107000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6895000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1379000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	16486000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	6895000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	14585000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-169641000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97899000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	284412000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	300898000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	203456000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44027000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23366000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12563000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39194000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28027000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8616000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	83221000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	51393000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	21179000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-83221000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-51393000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-21179000	USD
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	40000	USD
CY2020	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	319000	USD
CY2019	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	73000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1990000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-11702000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-81000	USD
CY2021	cmps	Fair Value Option Changes In Fair Value Gain Loss Excluding Due To Related Party FairValueOptionChangesInFairValueGainLossExcludingDueToRelatedParty	0	USD
CY2020	cmps	Fair Value Option Changes In Fair Value Gain Loss Excluding Due To Related Party FairValueOptionChangesInFairValueGainLossExcludingDueToRelatedParty	-1041000	USD
CY2019	cmps	Fair Value Option Changes In Fair Value Gain Loss Excluding Due To Related Party FairValueOptionChangesInFairValueGainLossExcludingDueToRelatedParty	-670000	USD
CY2021	cmps	Fair Value Option Changes In Fair Value Gain Loss Due To Related Party FairValueOptionChangesInFairValueGainLossDueToRelatedParty	0	USD
CY2020	cmps	Fair Value Option Changes In Fair Value Gain Loss Due To Related Party FairValueOptionChangesInFairValueGainLossDueToRelatedParty	-730000	USD
CY2019	cmps	Fair Value Option Changes In Fair Value Gain Loss Due To Related Party FairValueOptionChangesInFairValueGainLossDueToRelatedParty	-469000	USD
CY2021	cmps	Research And Development Tax Credit Income Tax Expense Benefit ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit	-9648000	USD
CY2020	cmps	Research And Development Tax Credit Income Tax Expense Benefit ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit	-4245000	USD
CY2019	cmps	Research And Development Tax Credit Income Tax Expense Benefit ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit	-2729000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11678000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8909000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1582000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-71543000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-60302000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19597000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	199000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-71742000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-60334000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19612000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5745000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	14683000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	337000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-77487000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45651000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19275000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.79
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.79
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.55
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.55
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.62
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.62
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39997587	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39997587	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16991664	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16991664	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7476422	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7476422	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-14368000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	337000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19612000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-30390000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2020	cmps	Stock Options Exercised Value StockOptionsExercisedValue	16000	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	0	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	121838000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	132765000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17983000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	14683000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-60334000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	196561000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	154794000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8639000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-5745000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-71742000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	284412000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-71742000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-60334000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19612000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	USD
CY2021	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
CY2020	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-1771000	USD
CY2019	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-1139000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	175000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	112000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	63000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-22000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	8639000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	17983000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	3253000	USD
CY2021	cmps	Operating Lease Expense And Right Of Use Asset Amortization OperatingLeaseExpenseAndRightOfUseAssetAmortization	1797000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	8984000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4490000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3430000	USD
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1880000	USD
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	877000	USD
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	221000	USD
CY2019	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	160000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	57000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-163000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1303000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	580000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5428000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2553000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	194000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67745000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41380000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17813000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	334000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	131000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	165000	USD
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	497000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-334000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-628000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-165000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	154794000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1852000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-60300000	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	132823000	USD
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	61316000	USD
CY2019	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	18434000	USD
CY2021	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	0	USD
CY2020	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	0	USD
CY2019	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	55000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	156646000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	194155000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18379000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-5576000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13225000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1676000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	82991000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	165372000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2077000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190356000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24984000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22907000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	273347000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190356000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24984000	USD
CY2021	cmps	Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities Including Initial Adioption RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption	5562000	USD
CY2021	cmps	Proceeds From Exercise Of Options Were Not Received And Recorded In Other Current Assets ProceedsFromExerciseOfOptionsWereNotReceivedAndRecordedInOtherCurrentAssets	53000	USD
CY2020	cmps	Proceeds From Exercise Of Options Were Not Received And Recorded In Other Current Assets ProceedsFromExerciseOfOptionsWereNotReceivedAndRecordedInOtherCurrentAssets	0	USD
CY2019	cmps	Proceeds From Exercise Of Options Were Not Received And Recorded In Other Current Assets ProceedsFromExerciseOfOptionsWereNotReceivedAndRecordedInOtherCurrentAssets	0	USD
CY2021	cmps	Deferred Offering Costs Included In Accrued Expenses DeferredOfferingCostsIncludedInAccruedExpenses	856000	USD
CY2020	cmps	Deferred Offering Costs Included In Accrued Expenses DeferredOfferingCostsIncludedInAccruedExpenses	0	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	273200000	USD
CY2019	cmps	Deferred Offering Costs Included In Accrued Expenses DeferredOfferingCostsIncludedInAccruedExpenses	58000	USD
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	21614000	USD
CY2019	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	273243000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190327000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24966000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	104000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	29000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	18000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	273347000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190356000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24984000	USD
CY2020Q3	us-gaap	Stock Issued During Period Shares Stock Splits StockIssuedDuringPeriodSharesStockSplits	1161	shares
CY2021Q4	cmps	Number Of Ordinary Shares Conversion Ratio NumberOfOrdinarySharesConversionRatio	1
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-71700000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the prepayment and accrual for research and development expenses, discount rates for leases, the fair value of ordinary shares before IPO, share-based compensation, measurement of the fair value of the Company’s convertible notes and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div>
CY2019Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	25000000.0	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places cash and cash equivalents in established financial institutions. The Company has no significant off-balance-</span></div>sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.
CY2021	cmps	Number Of Geographic Regions NumberOfGeographicRegions	2	region
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2000000.0	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-11700000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1000000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1000000	USD
CY2020	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-1800000	USD
CY2019	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-1100000	USD
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	18434000	USD
CY2019	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	1139000	USD
CY2019	cmps	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Exchange Difference FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExchangeDifference	1516000	USD
CY2021Q4	cmps	Research And Development Tax Credit Current ResearchAndDevelopmentTaxCreditCurrent	9587000	USD
CY2020Q4	cmps	Research And Development Tax Credit Current ResearchAndDevelopmentTaxCreditCurrent	4610000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3359000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3154000	USD
CY2021Q4	cmps	Prepaid Expense Research And Development Current PrepaidExpenseResearchAndDevelopmentCurrent	4562000	USD
CY2020Q4	cmps	Prepaid Expense Research And Development Current PrepaidExpenseResearchAndDevelopmentCurrent	2317000	USD
CY2021Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	1629000	USD
CY2020Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	1171000	USD
CY2021Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	840000	USD
CY2020Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	0	USD
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	274000	USD
CY2020Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	287000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1370000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	509000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	21621000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12048000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	756000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	433000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	358000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	188000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	398000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	245000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
CY2021Q4	cmps	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	3043000	USD
CY2020Q4	cmps	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	720000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1386000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	701000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5018000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1687000	USD
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	593000	USD
CY2020Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	384000	USD
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	243000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	268000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	413000	USD
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	10308000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4148000	USD
CY2020	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-1800000	USD
CY2019	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-1100000	USD
CY2019Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	9782505	shares
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	9782505	shares
CY2019Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	39279000	USD
CY2019Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	38908000	USD
CY2017Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	10551166	shares
CY2017Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	10551166	shares
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1476936	shares
CY2021	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	57875	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	406737	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1539411	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.82
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y6M29D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2284000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	3405490	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.17
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	429929	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.05
CY2021	cmps	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Or Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod	84632	shares
CY2021	cmps	Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled And Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledAndForfeituresInPeriodWeightedAverageExercisePrice	9.87
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4430340	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.61
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M19D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	186426000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1043702	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	36.11
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.55
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	313830	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	22.45
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3915503	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.53
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M20D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	51162000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2225758	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.13
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y2M26D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	43457000	USD
CY2021Q4	cmps	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedNumber	1689745	shares
CY2021Q4	cmps	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice	26.63
CY2021	cmps	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm	P9Y1M28D
CY2021Q4	cmps	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue	7705000	USD
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	429929	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	47400000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	12800000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	21.35
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.83
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.88
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	27400000	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	18100000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M23D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M12D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6736
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6610
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6340
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0095
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0043
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0188
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	35.21
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	12.58
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	2.16
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8639000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17983000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3253000	USD
CY2021Q4	cmps	Number Of Employees Amending Initial Share Option Contract NumberOfEmployeesAmendingInitialShareOptionContract	1	employee
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-72397000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-60522000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-19619000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	854000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	220000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	22000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-71543000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-60302000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19597000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	744000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	253000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	15000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	744000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	253000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	15000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-545000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-221000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-545000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-221000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-11458000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	29180000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8683000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	199000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-13592000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3724000	USD
CY2021	cmps	Effective Income Tax Rate Reconciliation Permanent Differences Amount EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount	69000	USD
CY2020	cmps	Effective Income Tax Rate Reconciliation Permanent Differences Amount EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount	340000	USD
CY2019	cmps	Effective Income Tax Rate Reconciliation Permanent Differences Amount EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount	238000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	3747000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	1664000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	1036000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2205000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-5000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	5000	USD
CY2021	cmps	Effective Income Tax Rate Reconciliation Deferred Tax Asset Reconciliation Amount EffectiveIncomeTaxRateReconciliationDeferredTaxAssetReconciliationAmount	-80000	USD
CY2020	cmps	Effective Income Tax Rate Reconciliation Deferred Tax Asset Reconciliation Amount EffectiveIncomeTaxRateReconciliationDeferredTaxAssetReconciliationAmount	-919000	USD
CY2019	cmps	Effective Income Tax Rate Reconciliation Deferred Tax Asset Reconciliation Amount EffectiveIncomeTaxRateReconciliationDeferredTaxAssetReconciliationAmount	0	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-8302000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	0	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	0	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-10147000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-837000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-111000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	255000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	199000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35947000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10075000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2936000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	169000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	62000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	757000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6232000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3128000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	42348000	USD
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	53000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10137000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3693000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41483000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13000000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3665000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	99000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	44000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	30000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	99000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	-3084000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	28000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	766000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	221000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	144000000	USD
CY2019Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	17700000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13000000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3665000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1321000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41483000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13000000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3665000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-71742000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-60334000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19612000	USD
CY2021	cmps	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-71742000	USD
CY2020	cmps	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-60334000	USD
CY2019	cmps	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-19612000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39997587	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39997587	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16991664	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16991664	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7476422	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7476422	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.79
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.79
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.55
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.55
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.62
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.62
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4513000	USD
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4088518	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4661579	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11321916	shares
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	142000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1844000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	0	USD
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	86000	USD
CY2021	us-gaap	Lease Cost LeaseCost	1930000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1971000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y7M20D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0499
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2285000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1471000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3756000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3614000	USD
CY2021	us-gaap	Lease Cost LeaseCost	1900000	USD
CY2020	us-gaap	Lease Cost LeaseCost	1000000.0	USD
CY2019	us-gaap	Lease Cost LeaseCost	400000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	100000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	100000	USD
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0	USD

Files In Submission

Name	View Source	Status
0001628280-22-003651-index-headers.html	Edgar Link	pending
0001628280-22-003651-index.html	Edgar Link	pending
0001628280-22-003651.txt	Edgar Link	pending
0001628280-22-003651-xbrl.zip	Edgar Link	pending
bioinnovationlabsllc_ser.htm	Edgar Link	pending
bioinnovationlabsllc_ser001.jpg	Edgar Link	pending
bioinnovationlabsllc_ser002.jpg	Edgar Link	pending
bioinnovationlabsllc_ser003.jpg	Edgar Link	pending
bioinnovationlabsllc_ser004.jpg	Edgar Link	pending
bioinnovationlabsllc_ser005.jpg	Edgar Link	pending
bioinnovationlabsllc_ser006.jpg	Edgar Link	pending
bioinnovationlabsllc_ser007.jpg	Edgar Link	pending
bioinnovationlabsllc_ser008.jpg	Edgar Link	pending
bioinnovationlabsllc_ser009.jpg	Edgar Link	pending
bioinnovationlabsllc_ser010.jpg	Edgar Link	pending
cmps-20211231.htm	Edgar Link	pending
cmps-20211231.xsd	Edgar Link	pending
cmps-20211231_cal.xml	Edgar Link	unprocessable
cmps-20211231_def.xml	Edgar Link	unprocessable
cmps-20211231_g1.jpg	Edgar Link	pending
cmps-20211231_g10.jpg	Edgar Link	pending
cmps-20211231_g11.jpg	Edgar Link	pending
cmps-20211231_g12.jpg	Edgar Link	pending
cmps-20211231_g13.jpg	Edgar Link	pending
cmps-20211231_g14.jpg	Edgar Link	pending
cmps-20211231_g15.jpg	Edgar Link	pending
cmps-20211231_g16.jpg	Edgar Link	pending
cmps-20211231_g17.jpg	Edgar Link	pending
cmps-20211231_g18.jpg	Edgar Link	pending
cmps-20211231_g19.jpg	Edgar Link	pending
cmps-20211231_g2.jpg	Edgar Link	pending
cmps-20211231_g20.jpg	Edgar Link	pending
cmps-20211231_g3.jpg	Edgar Link	pending
cmps-20211231_g4.jpg	Edgar Link	pending
cmps-20211231_g5.jpg	Edgar Link	pending
cmps-20211231_g6.jpg	Edgar Link	pending
cmps-20211231_g7.jpg	Edgar Link	pending
cmps-20211231_g8.jpg	Edgar Link	pending
cmps-20211231_g9.jpg	Edgar Link	pending
cmps-20211231_htm.xml	Edgar Link	completed
cmps-20211231_lab.xml	Edgar Link	unprocessable
cmps-20211231_pre.xml	Edgar Link	unprocessable
compass_servicexagreementx.htm	Edgar Link	pending
exbibit311gg.htm	Edgar Link	pending
exhibit312mf.htm	Edgar Link	pending
exhibit321gg.htm	Edgar Link	pending
exhibit322mf.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pwcconsent2021.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
sanfrancisco164townsends.htm	Edgar Link	pending
sanfrancisco164townsends001.jpg	Edgar Link	pending
sanfrancisco164townsends002.jpg	Edgar Link	pending
sanfrancisco164townsends003.jpg	Edgar Link	pending
sanfrancisco164townsends004.jpg	Edgar Link	pending
sanfrancisco164townsends005.jpg	Edgar Link	pending
sanfrancisco164townsends006.jpg	Edgar Link	pending
sanfrancisco164townsends007.jpg	Edgar Link	pending
sanfrancisco164townsends008.jpg	Edgar Link	pending
sanfrancisco164townsends009.jpg	Edgar Link	pending
sanfrancisco164townsends010.jpg	Edgar Link	pending
sanfrancisco164townsends011.jpg	Edgar Link	pending
sanfrancisco164townsends012.jpg	Edgar Link	pending
sanfrancisco164townsends013.jpg	Edgar Link	pending
sanfrancisco164townsends014.jpg	Edgar Link	pending
sanfrancisco164townsends015.jpg	Edgar Link	pending
sanfrancisco164townsends016.jpg	Edgar Link	pending
sanfrancisco164townsends017.jpg	Edgar Link	pending
sanfrancisco164townsends018.jpg	Edgar Link	pending
sanfrancisco164townsends019.jpg	Edgar Link	pending
sanfrancisco164townsends020.jpg	Edgar Link	pending
sanfrancisco164townsends021.jpg	Edgar Link	pending
sanfrancisco164townsends022.jpg	Edgar Link	pending
sanfrancisco164townsends023.jpg	Edgar Link	pending
sanfrancisco164townsends024.jpg	Edgar Link	pending
sanfrancisco164townsends025.jpg	Edgar Link	pending
sanfrancisco164townsends026.jpg	Edgar Link	pending
sanfrancisco164townsends027.jpg	Edgar Link	pending
sanfrancisco164townsends028.jpg	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CMPS
Compass Pathways PLC Stock $cmps

2021 Form 10-K Financial Statement

#000162828022003651 Filed on February 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CMPS Compass Pathways PLC Stock $cmps

2021 Form 10-K Financial Statement

#000162828022003651 Filed on February 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CMPS
Compass Pathways PLC Stock $cmps